AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06468865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor (Dexcom® G7)
Description: Continuous glucose monitors measures glucose levels in the interstitial fluid every 5 minutes
Study NCT05216380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActivityLink
Description: ActivityLink is an implementation program using:~1. Didactic and experiential training sessions for clinic staff to conduct referrals~2. Secure electronic referral webform to refer patients using their email address and phone number~3. Messaging sent to the patient and provider that they have been referred to a program~4. Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~5. Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot
Study NCT04234451 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle. The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
Study NCT06265441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance in which the adductor canal is identified and 20 ml of 0.25% bupivacaine will be injected
Description: The patients in group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance (SonoSite™, Inc., Bothell, WA 98021, USA) in which the patients are placed in the supine position with the arms resting comfortably across the chest and the affected lower extremity is externally rotated. Adductor canal was identified beneath the sartorius muscle and 22-gauge 90-mm spinal needle is inserted from anterolateral to posteromedial direction at a point approximately at the junction between the middle and distal third of the thigh on the anteromedial femur, this location is called mid adductor canal, then 20 ml of 0.25% bupivacaine is injected in the canal
Study NCT06265441 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B will receive adductor canal block under ultrasound guide 20 ml bupivacaine 0.25% and IPACK block under direct visualization of ultrasound of 20 ml bupivacaine 0.25%
Description: The patients in Group B will receive adductor canal block as described in group A then IPACK block, in which the patients are placed in a supine position and knee is placed in position of 90° flexion. A low-frequency ultrasound probe is positioned in the popliteal crease 1 finger breadth above the patella, and a spinal needle is inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle is placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.25% bupivacaine is injected while the needle is being withdrawn after negative aspiration.
Study NCT06086314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurorehabilitation program with functional reaching training without device.
Description: Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Doing functional stretching to the anterior, right and left while standing.
Study NCT04192929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band imaging
Description: Blue light is used during withdrawal phase instead of the regular white light to highlight surface changes
Study NCT04192929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Indigo carmine will be sprayed during withdrawal phase of colonoscopy
Study NCT04192929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High definition white light endoscopy
Description: High definition equipment will be used to perform colonoscopy
Study NCT06580561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise coaching
Description: This is a 6-session personalized exercise coaching program (delivered over 8 weeks).~All participants will complete six 30-minute scheduled online or phone sessions with a health coach as part of a manualized personalized exercise program (once per week for the first four sessions and then once every two weeks for the remaining two sessions).
Study NCT06580561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for Insomnia
Description: This is a 6-week course of automated, digitally delivered cognitive behavioral therapy for insomnia delivered by the online program Sleepio. The weekly sessions will last approximately 15-20 minutes.~Session content comprises evidence-based cognitive and behavioral techniques including Stimulus Control Therapy and Sleep Restriction Therapy, sleep hygiene education, and relaxation exercises.
Study NCT06293352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: All-cement articulating spacer
Description: Two-stage intervention
Study NCT06293352 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: All-cement articulating spacer
Description: Two-stage intervention
Study NCT06293352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durable, real-component articulating spacer
Description: Single stage intervention
Study NCT06293352 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Durable, real-component articulating spacer
Description: Single stage intervention
Study NCT06293352 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rigid Spacer
Description: Observation intervention
Study NCT05006560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (usual care)
Description: Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
Study NCT05006560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program
Description: Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
Study NCT05006560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: After care: Exercise and physical activity promotion
Description: Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app.
Study NCT05006573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Study NCT05006573 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Benralizumab
Description: Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Study NCT04381013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emergency Ventilator Splitter
Description: Device to enable oxygen delivery to two patients independently from a single ventilator.
Study NCT05035628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise training
Description: Participants will follow a 2-month exercise training program, thrice-weekly trainings. The training sessions will start with a 5-min warmup, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with respiratory exercises and cool down period (10 min). Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test.~A certified kinesiologist will supervise trainings. Heart rate, oxygen saturation and rating of perceived exertion (Borg Scale, 6-20) will be measured during training sessions.
Study NCT06110910 — intervention group
Intervention type: DRUG
Intervention: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)
Description: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
Study NCT04482062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards EVOQUE System
Description: Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT
Study NCT04482062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Optimal Medical Therapy
Study NCT05665881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: vasopressor
Study NCT05665881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: vasopressor
Study NCT05665881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: vasopressor
Study NCT06381791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: 150mg of Epidiolex
Study NCT06381791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: 150mg of Placebo oral solution
Study NCT04685031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Description: after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
Study NCT04685031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Topical
Description: after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
Study NCT05736510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural sound
Description: When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation.
Study NCT05736510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation.
Study NCT05268107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16.
Study NCT04832776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: one group plus cetuximab
Study NCT04949399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Injection
Study NCT04832776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: one group plus bevacizumab
Study NCT04832776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI
Description: FOLFOXIRI
Study NCT04832776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: FOLFOXIRI
Study NCT05091372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards\*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~\*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician.
Study NCT05091372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment.
Study NCT06654700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine (CHO Cell)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
Study NCT06593054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: Ceftibuten dihydrate, formulated in capsules
Study NCT06593054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avibactam prodrug
Description: Avibactam prodrug, formulated in capsules
Study NCT06593054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTB-AVP in Tablet
Description: ceftibuten and avibactam prodrug, in Tablet formulation
Study NCT06070597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclepertin
Description: Iclepertin
Study NCT06070597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclepertin Placebo
Description: Placebo to Iclepertin
Study NCT06070597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin
Study NCT05909241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA1202
Description: BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B.
Study NCT06070597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo Moxifloxacin
Study NCT05674643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound Baseline Scans
Description: The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.
Study NCT05674643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Acetaminophen Absorption Test (AAT)
Description: Prior to starting the AAT, a baseline plasma acetaminophen level (250 microliters) will be obtained from the intravenous catheter. The subject will then be given 12.5 mg/kg or max 650mg of single batch 32mg/mL acetaminophen followed by 6oz of water PO. Up to 3 additional small volume blood samples will be drawn for acetaminophen levels.~These additional blood samples (250 microliters each) will be obtained to measure acetaminophen plasma levels at the following goal intervals after acetaminophen administration.T1:10-20 mins, T2:35-45 mins, T3: 60mins. At the time of each lab draw gastric ultrasound will be assessed by the expert scanner to correlate gastric ultrasound with the acetaminophen absorption test as a gold-standard of gastric emptying.
Study NCT05674643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound Serial Scans
Description: Cohort 1 will have multiple scans as part of assessing gastric emptying. These sequential scans after the baseline assessment will be done in line with the Acetaminophen Absorption Test timeline (T1:10-20 mins, T2:35-45 mins, T3: 60mins) and will be performed by an expert scanner only.
Study NCT06610526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin by oral administration
Study NCT06611644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients in this group will receive an Erector Spinae Plane (ESP) block in addition to standard postoperative care. The ESP block will be performed under ultrasound guidance. A needle will be advanced in-plane or out-of-plane, targeting the lateral aspect of the T6 transverse process. Local anesthetic (20 to 30 ml) will be injected into the fascial plane between the erector spinae muscle and the transverse process. This block is intended to provide postoperative analgesia by blocking the transmission of pain through the thoracic spinal nerves.
Study NCT06611644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPSIPB blcok
Description: Patients in this group will receive a Serratus Posterior Superior Intercostal Plane (SPSIP) block along with standard postoperative care. The SPSIP block will be performed under ultrasound guidance, where the needle is advanced between the second and third ribs towards the medial aspect of the scapula. Local anesthetic 20 to 30 ml) will be injected into the fascial plane between the serratus posterior superior muscle and the intercostal muscles after confirming needle placement with hydrodissection using 1-2 ml of saline. This block is intended to provide broad analgesia across the upper thoracic dermatomes, from C3 to T7, to control postoperative pain.
Study NCT06611644 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients in the control group will receive standard postoperative pain management without any regional block intervention. This will include the administration of systemic analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs). Opioid analgesics will be administered as needed based on the patient's pain level. Pain management will be conducted according to the standard protocol followed for breast surgery patients.
Study NCT06611761 — intervention group
Intervention type: PROCEDURE
Intervention: Shoulder arthroscopy
Description: Shoulder arthroscopy in procedures that cause intense postoperative pain